Penumbra, Inc. (PEN)

Market Cap	13.29B +30.2%
Revenue (ttm)	1.33B +14.6%
Net Income	164.03M +374.8%
EPS	4.14 +367.3%
Shares Out	39.16M
PE Ratio	82.01
Forward PE	72.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618,246
Open	341.00
Previous Close	340.68
Day's Range	339.25 - 341.29
52-Week Range	221.26 - 362.41
Beta	0.81
Analysts	Buy
Price Target	350.94 (+3.41%)
Earnings Date	Feb 23, 2026

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,500
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Analyst Summary

According to 18 analysts, the average rating for PEN stock is "Buy." The 12-month stock price target is $350.94, which is an increase of 3.41% from the latest price.

Price Target

$350.94

(3.41% upside)

Analyst Consensus: Buy